• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于阿尔茨海默病病理的主要血液检测的头对头比较。

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

机构信息

Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.

出版信息

Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.

DOI:10.1002/alz.14315
PMID:39394841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11567821/
Abstract

INTRODUCTION

Blood tests have the potential to improve the accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes.

METHODS

Plasma samples from the Alzheimer's Disease Neuroimaging Initiative were assayed with AD blood tests from C2N Diagnostics, Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix. Outcomes measures were amyloid positron emission tomography (PET), tau PET, cortical thickness, and dementia severity. Logistic regression models assessed the classification accuracies of individual or combined plasma biomarkers for binarized outcomes, and Spearman correlations evaluated continuous relationships between individual plasma biomarkers and continuous outcomes.

RESULTS

Measures of plasma p-tau217, either individually or in combination with other plasma biomarkers, had the strongest relationships with all AD outcomes.

DISCUSSION

This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.

HIGHLIGHTS

Plasma p-tau217 measures most accurately classified amyloid and tau status. Plasma Aβ42/Aβ40 had relatively low accuracy in classification of amyloid status. Plasma p-tau217 measures had higher correlations with cortical thickness than NfL. Correlations of plasma biomarkers with dementia symptoms were relatively low.

摘要

简介

血液检测有可能提高阿尔茨海默病（AD）临床诊断的准确性，从而使更多的患者能够接受 AD 特异性治疗。本研究比较了几种具有领先地位的商业化血液检测方法，用于检测淀粉样蛋白病理学和其他与 AD 相关的结果。

方法

使用 C2N 诊断公司、富士瑞必欧诊断公司、ALZPath、杨森制药公司、罗氏诊断公司和 Quanterix 公司的 AD 血液检测方法，对来自阿尔茨海默病神经影像学倡议的血浆样本进行检测。检测结果包括淀粉样蛋白正电子发射断层扫描（PET）、tau PET、皮质厚度和痴呆严重程度。逻辑回归模型评估了单个或组合血浆生物标志物对二值化结果的分类准确性，Spearman 相关性评估了单个血浆生物标志物与连续结果之间的连续关系。

结果

血浆 p-tau217 的测量值，无论是单独测量还是与其他血浆生物标志物结合测量，与所有 AD 结果的相关性最强。

讨论

本研究确定了最能准确分类淀粉样蛋白病理学和其他 AD 相关结果的血浆生物标志物分析物和检测方法。

要点

血浆 p-tau217 测量值最能准确分类淀粉样蛋白和 tau 状态。血浆 Aβ42/Aβ40 对淀粉样蛋白状态的分类准确性相对较低。与 NfL 相比，血浆 p-tau217 测量值与皮质厚度的相关性更高。血浆生物标志物与痴呆症状的相关性相对较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/c569448949a6/ALZ-20-8074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/1ee487e6d0ca/ALZ-20-8074-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/c5c8f4415b44/ALZ-20-8074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/64750b46c289/ALZ-20-8074-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/5acb55c7cf39/ALZ-20-8074-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/a5cb8428a18b/ALZ-20-8074-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/757fd872b03e/ALZ-20-8074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/bcf23418384c/ALZ-20-8074-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/c569448949a6/ALZ-20-8074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/1ee487e6d0ca/ALZ-20-8074-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/c5c8f4415b44/ALZ-20-8074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/64750b46c289/ALZ-20-8074-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/5acb55c7cf39/ALZ-20-8074-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/a5cb8428a18b/ALZ-20-8074-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/757fd872b03e/ALZ-20-8074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/bcf23418384c/ALZ-20-8074-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de51/11567821/c569448949a6/ALZ-20-8074-g003.jpg

相似文献

1
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.用于阿尔茨海默病病理的主要血液检测的头对头比较。
Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.
2
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.肾功能对阿尔茨海默病血液生物标志物的影响：对预测淀粉样蛋白-β阳性的意义。
Alzheimers Res Ther. 2025 Feb 19;17(1):48. doi: 10.1186/s13195-025-01692-z.
3
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study.利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau蛋白脑沉积及认知衰退：一项纵向队列研究。
Lancet Neurol. 2025 Jul;24(7):591-600. doi: 10.1016/S1474-4422(25)00158-9.
4
Diagnostic Performance of Eight Blood-based Biomarkers in a Well-characterized Korean Cohort of Preclinical Alzheimer's Disease.八项血液生物标志物在特征明确的韩国临床前阿尔茨海默病队列中的诊断性能
Ann Lab Med. 2025 May 12. doi: 10.3343/alm.2024.0498.
5
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study.血浆Aβ42/40比值、磷酸化tau181、胶质纤维酸性蛋白（GFAP）和神经丝轻链（NfL）在阿尔茨海默病和非阿尔茨海默病性痴呆连续病程中的诊断性能：一项国际多中心研究
Alzheimers Dement. 2025 Jun;21(6):e14573. doi: 10.1002/alz.14573.
6
Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community.匹兹堡血浆p-tau217：社区中常染色体显性和散发性阿尔茨海默病的分类准确率。
Alzheimers Dement. 2025 Jul;21(7):e70409. doi: 10.1002/alz.70409.
7
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.阿尔茨海默病病理学主要血液检测的直接比较。
medRxiv. 2024 Jul 3:2024.06.12.24308839. doi: 10.1101/2024.06.12.24308839.
8
Plasma p-tau and neurofilament/p-tau ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration.血浆磷酸化tau蛋白及神经丝蛋白/磷酸化tau蛋白比值在鉴别阿尔茨海默病与额颞叶变性相关综合征中的作用
Alzheimers Dement. 2025 Feb;21(2):e14482. doi: 10.1002/alz.14482. Epub 2025 Jan 8.
9
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.多分析物蛋白质组学分析鉴定出临床前阿尔茨海默病患者血液中的神经炎症、脑血管和突触生物标志物。
Mol Neurodegener. 2024 Oct 10;19(1):68. doi: 10.1186/s13024-024-00753-5.
10
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.阿尔茨海默病生物学和临床分期修订标准的评估
JAMA Neurol. 2025 May 19. doi: 10.1001/jamaneurol.2025.1100.

引用本文的文献

1
Electronic health records to test multimorbidity influences to plasma biomarker interpretation for Alzheimer's disease.电子健康记录用于测试多种疾病对阿尔茨海默病血浆生物标志物解读的影响。
medRxiv. 2025 Aug 19:2025.08.16.25333799. doi: 10.1101/2025.08.16.25333799.
2
Stepwise approach to alzheimer's disease diagnosis in primary care using cognitive screening, risk factors, neuroimaging and plasma biomarkers.在初级保健中使用认知筛查、风险因素、神经影像学和血浆生物标志物对阿尔茨海默病进行逐步诊断的方法。
Sci Rep. 2025 Aug 27;15(1):31526. doi: 10.1038/s41598-025-17394-3.
3
Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease.

本文引用的文献

1
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.血浆磷酸化 tau 217 和 Aβ42/40 预测认知正常人群的早期脑 Aβ 蓄积。
JAMA Neurol. 2024 Sep 1;81(9):947-957. doi: 10.1001/jamaneurol.2024.2619.
2
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.用于在初级保健和二级保健中检测阿尔茨海默病的血液生物标志物。
JAMA. 2024 Oct 15;332(15):1245-1257. doi: 10.1001/jama.2024.13855.
3
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.
通过种族比较血浆p-tau217/Aβ42、p-tau217和Aβ42/Aβ40生物标志物以检测阿尔茨海默病。
Alzheimers Dement. 2025 Aug;21(8):e70469. doi: 10.1002/alz.70469.
4
Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups.血浆磷酸化tau 217和淀粉样蛋白β 42/40用于亚组中的淀粉样蛋白风险评估
Alzheimers Res Ther. 2025 Aug 7;17(1):184. doi: 10.1186/s13195-025-01826-3.
5
Cognitive impairment and p-tau217 are high in a vascular patient cohort.在一个血管病患者队列中，认知障碍和磷酸化tau217水平较高。
Alzheimers Dement. 2025 Aug;21(8):e70565. doi: 10.1002/alz.70565.
6
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.阿尔茨海默病协会关于在专科护理环境中对疑似阿尔茨海默病进行诊断检查时使用血液生物标志物的临床实践指南。
Alzheimers Dement. 2025 Jul;21(7):e70535. doi: 10.1002/alz.70535.
7
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.血浆生物标志物可识别无痴呆症的基于人群队列中的脑淀粉样蛋白、tau蛋白和神经退行性变异常。
Alzheimers Res Ther. 2025 Jul 25;17(1):173. doi: 10.1186/s13195-025-01803-w.
8
Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.神经退行性疾病中靶向小胶质细胞的生物标志物与治疗策略：现状与未来方向
Mol Neurodegener. 2025 Jul 10;20(1):82. doi: 10.1186/s13024-025-00867-4.
9
Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease.肥胖对阿尔茨海默病血浆生物标志物及淀粉样蛋白PET轨迹的影响。
Alzheimers Dement (Amst). 2025 Jul 3;17(3):e70143. doi: 10.1002/dad2.70143. eCollection 2025 Jul-Sep.
10
Tau burden is best captured by magnitude and extent: Tau-MaX as a measure of global tau.tau蛋白负荷最好通过数量和范围来体现：Tau-MaX作为衡量整体tau蛋白的指标。
Alzheimers Dement. 2025 Jul;21(7):e70346. doi: 10.1002/alz.70346.
修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
4
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.可接受的淀粉样蛋白病理血生物标志物检测性能——来自全球阿尔茨海默病首席执行官倡议的建议。
Nat Rev Neurol. 2024 Jul;20(7):426-439. doi: 10.1038/s41582-024-00977-5. Epub 2024 Jun 12.
5
Disease staging of Alzheimer's disease using a CSF-based biomarker model.采用基于脑脊液生物标志物模型对阿尔茨海默病进行疾病分期。
Nat Aging. 2024 May;4(5):694-708. doi: 10.1038/s43587-024-00599-y. Epub 2024 Mar 21.
6
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.PrecivityAD2 血液检测的临床验证：一种基于质谱的检测方法，采用 %p-tau217 和 Aβ42/40 比值相结合的算法来识别脑淀粉样蛋白的存在。
Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764. Epub 2024 Mar 16.
7
Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology.两种血浆 p-tau217 检测方法在阿尔茨海默病检测和监测中的比较。
EBioMedicine. 2024 Apr;102:105046. doi: 10.1016/j.ebiom.2024.105046. Epub 2024 Mar 11.
8
Biomarker-based staging of Alzheimer disease: rationale and clinical applications.基于生物标志物的阿尔茨海默病分期：原理与临床应用。
Nat Rev Neurol. 2024 Apr;20(4):232-244. doi: 10.1038/s41582-024-00942-2. Epub 2024 Mar 1.
9
Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.散发性阿尔茨海默病从症状出现到估计年份的生物标志物变化时间。
Ann Neurol. 2024 May;95(5):951-965. doi: 10.1002/ana.26891. Epub 2024 Feb 24.
10
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.阿尔茨海默病的高精度血液检测在准确性上可与临床脑脊液检测相媲美或优于后者。
Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.